Cefepime + Tazobactum in pharma franchise in Maharashtra

Cefepime + Tazobactum in PCD pharma franchise in Chandigarh

Cefepime + Tazobactum in top pharma company in Shillong

Cefepime + Tazobactum in pcd pharma supplier in Madurai

Cefepime + Tazobactum in phama franchise company in India
Cefepime + Tazobactum in phama distributor in Siliguri

Home/Products /cefepime-1000mg-tazobactum-125mg-injection

Tillpime TZ Injection

Composition : Cefepime (1000mg) + Tazobactum (125mg)

Dosage Form : Injection

Packaging Type : Vial + Water

Packaging : 1

Price : ₹595/-

Tillpime TZ Injection combines cefepime and tazobactam, offering a powerful therapeutic option for treating a variety of serious bacterial infections. Cefepime, a fourth-generation cephalosporin antibiotic, exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria. It works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death. Tazobactam, a beta-lactamase inhibitor, enhances the efficacy of cefepime by preventing the breakdown of the antibiotic by resistant bacterial enzymes, thereby extending its spectrum of activity against resistant strains.

This formulation is particularly effective in treating conditions such as pneumonia, urinary tract infections, skin infections, and intra-abdominal infections caused by susceptible organisms. Due to its ability to penetrate well into tissues, Tillpime TZ is also utilized in the management of febrile neutropenia and other severe infections where rapid therapeutic intervention is critical.

Read More

About the Product

Tillpime TZ Injection combines cefepime and tazobactam, offering a powerful therapeutic option for treating a variety of serious bacterial infections. Cefepime, a fourth-generation cephalosporin antibiotic, exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria. It works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death. Tazobactam, a beta-lactamase inhibitor, enhances the efficacy of cefepime by preventing the breakdown of the antibiotic by resistant bacterial enzymes, thereby extending its spectrum of activity against resistant strains.

This formulation is particularly effective in treating conditions such as pneumonia, urinary tract infections, skin infections, and intra-abdominal infections caused by susceptible organisms. Due to its ability to penetrate well into tissues, Tillpime TZ is also utilized in the management of febrile neutropenia and other severe infections where rapid therapeutic intervention is critical.

Common side effects may include diarrhea, rash, nausea, headache, and potential allergic reactions. Serious side effects can occur, and patients should be monitored for signs of anaphylaxis or superinfection.

Tillpime TZ is indicated for the treatment of moderate to severe bacterial infections, including pneumonia, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.

Use under medical supervision only; not recommended for patients with a known allergy to cephalosporins or beta-lactams. Always consult a healthcare professional before administration. Tillpime TZ Injection is administered intravenously, and dosing should be tailored to the individual patient's needs, taking into account the severity of the infection and renal function. Regular monitoring during treatment is essential to ensure therapeutic efficacy and to mitigate potential adverse effects. Always adhere to the recommended dosage guidelines to optimize treatment outcomes.

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation